Merck Buying Drug Targeting B-Cell Diseases for Up to $1.3 Billion




Merck has struck a deal worth up to $1.3 billion to buy an investigational drug targeting B-cell associated diseases.

Leave a Reply

Your email address will not be published. Required fields are marked *